ADG106 + Doxorubicin + Cyclophosphamide + Paclitaxel
Phase 1/2Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-negative Breast Cancer
Conditions
HER2-negative Breast Cancer, Advanced Solid Tumor
Trial Timeline
May 19, 2022 → Feb 1, 2030
NCT ID
NCT05275777About ADG106 + Doxorubicin + Cyclophosphamide + Paclitaxel
ADG106 + Doxorubicin + Cyclophosphamide + Paclitaxel is a phase 1/2 stage product being developed by Adagene for HER2-negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05275777. Target conditions include HER2-negative Breast Cancer, Advanced Solid Tumor.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05275777 | Phase 1/2 | Active |
Competing Products
19 competing products in HER2-negative Breast Cancer